¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"adrenergic neurotransmitter"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® neurotransmitter ÇÑ±Û ½Å°æÀü´Þ¹°Áú
¼³¸í   
  Ã¼³»ÀÇ ½Å°æ ¼¼Æ÷¿¡¼­ ¹æÃâµÇ¸ç ÀÎÁ¢Çϴ ½Å°æ¼¼Æ÷³ª ±ÙÀ°¿¡ Á¤º¸¸¦ Àü´ÞÇϴ ¹°Áú. ½Å°æ¼¼Æ÷³»¿¡¼­ ÇÕ¼ºµÇ¾î¼­ ½Å°æÁ¾¸»ÀÇ ¿¬Á¢¼ÒÆ÷¿¡ ÀúÀåµÈ´Ù. Àڱؿ¡ ÀÇÇØ¼­ ¿¬Á¢°£±Ø¿¡ À¯¸®µÇ¾î¼­ ¼ö¿ëü¿Í °áÇÕÇÏ¿© Á¤º¸¸¦ ´ÙÀ½ ¼¼Æ÷·Î ÀüÇÑ´Ù. Àü±âÀûÀ¸·Î°¡ ¾Æ´Ï¶ó È­Çй°Áú¿¡ ÀÇÇØ¼­ ¿¬Á¢°£±ØÀ» °ÅÃÄ Á¤º¸¸¦ ÀüÇϱ⠶§¹®¿¡ È­ÇÐÀü´Þ¹°ÁúÀ̶ó°íµµ ÇÑ´Ù. ¿¬Á¢Èĸ·(°æ¿ì¿¡ µû¶ó¼­ ¿¬Á¢Àü¸·)À» ÈïºÐ(Å»ºÐ±Ø)½Ã۴ ÈïºÐ¼ºÀü´Þ¹°Áú°ú ¾ïÁ¦(°úºÐ±Ø)Çϴ ¾ïÁ¦¼º Àü´Þ¹°ÁúÀÌ ÀÖ´Ù. ¾Æ¼¼Æ¿Äݸ°, ³ë¸£¿¡Çdz×ÇÁ, µµÆÄ¹Î, ±Û¸®½Å, ¥ã-¾Æ¹Ì³ëºäÄ¥»ê(GABA)µî °°Àº ½Å°æÀü´Þ¹°ÁúÀ̶󵵠¼ö¿ëü¿¡ µû¶ó¼­ ÈïºÐ¼º°ú ¾ïÁ¦¼ºÀ¸·Îµµ ÀÛ¿ëÇϴ °Íµµ ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • neurotransmitter
    ½Å°æÀü´Þ¹°Áú
  • adrenergic
    1. ¾Æµå·¹³¯¸°- 2. ¾Æµå·¹³¯¸°¼º¾à
  • adrenergic antagonist
    ¾Æµå·¹³¯¸°´ëÇ×Á¦, ¾Æµå·¹³¯¸°±æÇ×Á¦
  • adrenergic blocker
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦
  • adrenergic drug
    ¾Æµå·¹³¯¸°ÀÛ¿ë¾à
  • adrenergic fiber
    ¾Æµå·¹³¯¸°¼¶À¯
  • adrenergic receptor
    ¾Æµå·¹³¯¸°¼ö¿ëü
  • beta-adrenergic receptor kinase
    º£Å¸¾Æµå·¹³¯¸°¼ö¿ëüÀλêÈ­È¿¼Ò
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • neurotransmitter
    ½Å°æÀü´Þ¹°Áú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • neurotransmitter
    ½Å°æÀü´Þ¹°Áú
  • adrenergic
    ¾Æµå·¹³¯¸°¼º¾à, ¾Æµå·¹³¯¸°-
  • adrenergic blocker
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦
  • adrenergic drug
    ¾Æµå·¹³¯¸°ÀÛ¿ë¾à
  • adrenergic fiber
    ¾Æµå·¹³¯¸°¼¶À¯
  • adrenergic receptor
    ¾Æµå·¹³¯¸°¼ö¿ëü
  • adrenergic antagonist
    ¾Æµå·¹³¯¸°´ëÇ×Á¦
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦
  • beta-adrenergic receptor kinase
    º£Å¸¾Æµå·¹³¯¸°¼º¼ö¿ëüÀλêÈ­È¿¼Ò
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adrenergic stimulating drug
    ¾Æµå·¹³¯¸°ÈïºÐ¾à, ¾Æµå·¹³¯¸°ÀÚ±ØÁ¦.
  • adrenergic tone
    ¾Æµå·¹³¯¸°¼º ±äÀåµµ
  • adrenergic transmission
    ¾Æµå·¹³¯¸°¼ºÀü´Þ
  • adrenergic urticaria
    ¾Æµå·¹³¯¸°¼º µÎµå·¯±â
  • adrenoceptor =adrenergic
    ¾Æµå·¹³¯¸°(¼º)¼ö¿ëü(áôé»ô÷).
  • alpha-adrenergic agonist
    ¾ËÆÄ¾Æµå·¹³¯¸°ÃËÁøÁ¦
  • alpha-adrenergic antagonist
    ¾ËÆÄ¾Æµå·¹³¯¸°±æÇ×Á¦
  • alpha-adrenergic receptor
    ¾ËÆÄ-¾Æµå·¹³¯¸°¼ö¿ëü.
  • alpha-adrenergic receptor
    ¾ËÆÄ¾Æµå·¹³¯¸°¼ö¿ëü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adrenergic neurotransmitter
    ¾Æµå·¹³¯¸°¼º ½Å°æÀü´Þ¹°Áú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cholinergic neurotransmitter
    Äݸ°¼º ½Å°æÀü´Þ¹°Áú
  • nerve transmitter substance =neurotransmitter
    ½Å°æÀü´Þ¹°Áú(~îîÓ¹Úªòõ).
  • neurotransmitter
    ½Å°æÀü´Þ¹°Áú
  • neurotransmitter =nerve transmitter s
    ½Å°æÀü´Þ¹°Áú.
  • neurotransmitter =nerve transmitter substance
    ½Å°æÀü´Þ¹°Áú.
  • neurotransmitter [=nerve transmitter substance]
    ½Å°æÀü´Þ¹°Áú
  • adrenergic
    ¾Æµå·¹³¯¸°¼º, ¾Æµå·¹³¯¸°ÀÛµ¿¼º, ¾Æµå·¹³¯¸°(¼º)¾à.
  • adrenergic agonist
    ¾Æµå·¹³¯¸°¼ºÃËÁøÁ¦
  • adrenergic antagonist
    ¾Æµå·¹³¯¸° ±æÇ×¹°Áú
  • adrenergic antagonist
    ¾Æµå·¹³¯¸°¼º ±æÇ×Á¦
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦.
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°¼º Â÷´ÜÁ¦
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸°(¼º) ºÀ¼â<Â÷´Ü>¾à.
  • adrenergic drug =a. stimulating agent
    ¾Æµå·¹³¯¸°¾à.
  • adrenergic drug =a. stimulating agent
    ¾Æµå·¹³¯¸°¼º¾à¹°
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Neurotransmitter
    ½Å°æÀü´Þ¹°Áú
    [¿¾ ¿ë¾î] ½Å°æÀü´Þ¹°Áú
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • neurotransmitter
    ½Å°æÀü´Þ¹°Áú(ãêÌèîîÓ¹Úªòõ)
  • adrenergic
    ¾Æµå·¹³¯¸° ÀÛµ¿¼º(íÂÔÑàõ)
  • adrenergic receptor
    ¾Æµå·¹³¯¸°ÀÛµ¿(íÂÔÑ) ¼ö¿ëü(áôé»ô÷)
  • alpha adrenergic receptor
    ¾ËÆÄ¾Æµå·¹³ª¸°ÀÛµ¿¼º(íÂÔÑàõ) ¼ö¿ëü(áôé»ô÷)
  • beta adrenergic blocker
    º£Å¸ ¾Æµå·¹³¯¸°ÀÛµ¿(íÂÔÑ) Â÷´ÜÁ¦(ó´Ó¨ð¥)
  • beta adrenergic receptor
    º£Å¸ ¾Æµå·¹³¯¸° ¼ö¿ëü(áôé»ô÷)
  • dopamine adrenergic receptor
    "µµÆÄ¹Î ¾Æµå·¹³¯¸°ÀÛµ¿¼º(íÂÔÑàõ) ¼ö¿ëü(áôé»ô÷), (ÔÒ) adrenergic receptor"
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
NT, Nt NeuroTransmitter
BNT Boston Naming Test; brain neurotransmitter
ADRA1C alpha-1C-adrenergic receptor
ADRBK beta-1-adrenergic receptor kinase
ADRBR adrenergic beta-receptor
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AR 1-Adrenergic receptor
alpha(2)-AR alpha(2B)-adrenergic receptor
AR Alpha1-adrenergic receptors
alpha1-ARs Alpha1-adrenergic receptors
beta 2AR Beta 2-adrenergic receptors
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • adrenergic neurotransmitter
    ¾Æµå·¹³¯¸°¼º ½Å°æ Àü´Þ ¹°Áú
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • 2-adrenergic agonist
    2-¾Æµå·¹³¯¸° ÀÛ¿ëÁ¦, 2-¾Æµå·¹³¯¸° ÀÛµ¿Á¦
  • adrenergic agonist
    ¾Æµå·¹³¯¸°¼º ÀÛµ¿¾à
    ¾Æµå·¹³¯¸°¼º ¼ö¿ëü¸¦ ÈïºÐ½ÃÅ´À¸·Î½á È¿°ú¸¦ ³ªÅ¸³»´Â ¾à¹°. ´ë°Ô ¾Æ¹Î È­ÇÕ¹°À̹ǷΠ±³°¨½Å°æ À¯»ç ¾Æ¹ÎÀ̶ó°íµµ ÇÑ´Ù.
  • adrenergic blocking agent
    ¾Æµå·¹³¯¸° Â÷´ÜÁ¦
    ¾Æµå·¹³¯¸°¼º ¼ö¿ëü¿¡ ÀÛ¿ëÇÏ¿© ½Å°æ Àü´Þü¿Í ¼ö¿ëü°¡ °áÇÕÇÏÁö ¸øÇÏ°Ô ÇÔÀ¸·Î½á ±³°¨½Å°æ ÈïºÐ È¿°ú¸¦ ºÀ¼âÇÏ´Â ¾à¹°.
  • adrenergic fiber
    ¾Æµå·¹³¯¸°¼º ¼¶À¯
  • adrenergic stimulating drug
    ¾Æµå·¹³¯¸° ÈïºÐ ¾à, ¾Æµå·¹³¯¸°¼º ÈïºÐ¾à, ¾Æµå·¹³¯¸° ÀÚ±ØÁ¦, ¾Æµå·¹³¯¸°¼º ÀÚ±ØÁ¦
  • adrenergic transmission
    ¾Æµå·¹³¯¸°¼º Àü´Þ
    ³ë¸£¾Æµå·¹³¯¸° ¶Ç´Â ¾Æµå·¹³¯¸°À» Àü´Þ ¹°Áú·Î ÇÏ´Â ÈïºÐ Àü´Þ. ±³°¨½Å°æÀÇ ¹ß´ÜÀ» °ÅÀÇ À̰ÍÀÌ´Ù. ±³°¨ ½Å°æ ¼¶À¯°¡ ÈïºÐÇÏ¸é ¸»´Ü¿¡¼­ ³ë¸£¾Æµå·¹³¯¸° µîÀÌ ¹æÃâµÇ°í À̰ÍÀÌ È¿°ú±âÀÇ ¼ö¿ë±â¿¡ µµ´ÞÇØ ÈïºÐµÈ´Ù. ÈïºÐ
  • adrenergic urticaria
    ¾Æµå·¹³¯¸°¼º µÎµå·¯±â
  • alpha 1-adrenergic blocker
    ¾ËÆÄ 1-¾Æµå·¹³¯¸°¼º Â÷´Ü
  • alpha adrenergic antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸° ±æÇ×Á¦
  • alpha-adrenergic receptor
    ¾ËÆÄ-¾Æµå·¹³¯¸° ¼ö¿ëü
  • beta-adrenergic blocking agent
    º£Å¸ ¾Æµå·¹³¯¸°¼º Â÷´ÜÁ¦
  • ¥â-adrenergic

    ¥â-adrenergic agent (

    ¥â-adrenergic receptor blocking agent (º£Å¸ ¾Æµå·¹³¯¸°¼º ¼ö¿ëü Â÷´ÜÁ¦

CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
receptors, neurotransmitter Cell surface receptors that bind signalling molecules released by neurons and convert these signals into intracellular changes influencing the behaviour of cells. Neurotransmitter is used here in its most general sense, including not only messengers that act to regulate ion channels, but also those which act on second messenger systems and those which may act at a distance from their release sites. Included are receptors for neuromodulators, neuroregulators, neuromediators, and neurohumors, whether or not located at synapses.
(12 Dec 1998)
peptide neurotransmitter Small peptides used as primary or co transmitters in nerve cells for example FMRF amide, FLRFamide.
(18 Nov 1997)
neurotransmitter Any of a group of substances that are released on excitation from the axon terminal of a presynaptic neuron of the central or peripheral nervous system and travel across the synaptic cleft to either excite or inhibit the target cell. Among the many substances that have the properties of a neurotransmitter are acetylcholine, noradrenaline, adrenaline, dopamine, glycine, y aminobutyrate, glutamic acid, substance P, enkephalins, endorphins and serotonin.
(18 Nov 1997)
neurotransmitter agents Substances used for their pharmacological actions on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function.
(12 Dec 1998)
neurotransmitters and neurotransmitter agents A collective grouping for neurotransmitters and substances that act on the neurotransmitter system.
(12 Dec 1998)
neurotransmitter system A group of nerve cells that use the sameneurotransmitter to communicate.
(22 May 1997)
neurotransmitter uptake inhibitors Drugs that inhibit the transport of neurotransmitters into axon terminals or into storage vesicles within terminals. For many transmitters, uptake determines the time course of transmitter action so inhibiting uptake prolongs the activity of the transmitter. Blocking uptake may also deplete available transmitter stores. Many clinically important drugs are uptake inhibitors although the indirect reactions of the brain rather than the acute block of uptake itself is often responsible for the therapeutic effects.
(12 Dec 1998)
adrenergic <neurology, physiology> Refers to neurons that use catecholamines as neurotransmitters at a synapse when a nerve impulse passes i.e. The sympathetic fibres.
Also refers to neurones that are activated by, characteristic of or secreting adrenaline (adrenaline) or substances with similar activity.
(15 Jan 1998)
adrenergic agents Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.
(12 Dec 1998)
adrenergic agonists Drugs that bind to and activate adrenergic receptors.
(12 Dec 1998)
adrenergic alpha-agonists Drugs that selectively bind to and activate alpha adrenergic receptors.
(12 Dec 1998)
adrenergic alpha-antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
(12 Dec 1998)
adrenergic amine An agent that evokes responses similar to those produced by adrenergic nerve activity (e.g., epinephrine, ephedrine, isoproterenol).
Synonym: adrenergic amine, adrenomimetic amine, sympathetic amine.
(05 Mar 2000)
adrenergic antagonists Drugs that bind to but do not activate adrenergic receptors. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters epinephrine and norepinephrine.
(12 Dec 1998)
adrenergic beta-agonists Drugs that selectively bind to and activate beta-adrenergic receptors.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • neurotransmitter
    ½Å°æÀü´Þ¹°Áú
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á